637 related articles for article (PubMed ID: 21289624)
1. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
[TBL] [Abstract][Full Text] [Related]
2. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis.
Qin J; Wu SP; Creighton CJ; Dai F; Xie X; Cheng CM; Frolov A; Ayala G; Lin X; Feng XH; Ittmann MM; Tsai SJ; Tsai MJ; Tsai SY
Nature; 2013 Jan; 493(7431):236-40. PubMed ID: 23201680
[TBL] [Abstract][Full Text] [Related]
3. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.
Gerke TA; Martin NE; Ding Z; Nuttall EJ; Stack EC; Giovannucci E; Lis RT; Stampfer MJ; Kantoff PW; Parmigiani G; Loda M; Mucci LA
Prostate; 2015 Dec; 75(16):1926-33. PubMed ID: 26469352
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.
Sun B; Fan Y; Yang A; Liang L; Cao J
J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
[TBL] [Abstract][Full Text] [Related]
5. Opposing roles of TGFβ and BMP signaling in prostate cancer development.
Lu X; Jin EJ; Cheng X; Feng S; Shang X; Deng P; Jiang S; Chang Q; Rahmy S; Chaudhary S; Lu X; Zhao R; Wang YA; DePinho RA
Genes Dev; 2017 Dec; 31(23-24):2337-2342. PubMed ID: 29352019
[TBL] [Abstract][Full Text] [Related]
6. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
[TBL] [Abstract][Full Text] [Related]
7. Molecular predicator of metastatic cancer identified.
Printz C
Cancer; 2011 Jul; 117(13):2829. PubMed ID: 21692044
[No Abstract] [Full Text] [Related]
8. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
9. GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.
Yang X; Zhang Q; Li S; Devarajan R; Luo B; Tan Z; Wang Z; Giannareas N; Wenta T; Ma W; Li Y; Yang Y; Manninen A; Wu S; Wei GH
J Exp Clin Cancer Res; 2023 Aug; 42(1):198. PubMed ID: 37550764
[TBL] [Abstract][Full Text] [Related]
10. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
[TBL] [Abstract][Full Text] [Related]
11. Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin.
Qiao W; Li AG; Owens P; Xu X; Wang XJ; Deng CX
Oncogene; 2006 Jan; 25(2):207-17. PubMed ID: 16170355
[TBL] [Abstract][Full Text] [Related]
12. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
13. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.
Ju X; Casimiro MC; Gormley M; Meng H; Jiao X; Katiyar S; Crosariol M; Chen K; Wang M; Quong AA; Lisanti MP; Ertel A; Pestell RG
Cancer Res; 2014 Jan; 74(2):508-19. PubMed ID: 24282282
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer.
Alioui A; Dufour J; Leoni V; Loregger A; Moeton M; Iuliano L; Zerbinati C; Septier A; Val P; Fouache A; Russo V; Volle DH; Lobaccaro JA; Zelcer N; Baron S
Nat Commun; 2017 Sep; 8(1):445. PubMed ID: 28874658
[TBL] [Abstract][Full Text] [Related]
15. Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse.
Teng Y; Sun AN; Pan XC; Yang G; Yang LL; Wang MR; Yang X
Cancer Res; 2006 Jul; 66(14):6972-81. PubMed ID: 16849541
[TBL] [Abstract][Full Text] [Related]
16. BMP suppresses PTEN expression via RAS/ERK signaling.
Beck SE; Carethers JM
Cancer Biol Ther; 2007 Aug; 6(8):1313-7. PubMed ID: 18059158
[TBL] [Abstract][Full Text] [Related]
17. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
[TBL] [Abstract][Full Text] [Related]
18. A Transition Zone Showing Highly Discontinuous or Alternating Levels of Stem Cell and Proliferation Markers Characterizes the Development of PTEN-Haploinsufficient Colorectal Cancer.
Arvai KJ; Hsu YH; Lee LA; Jones D
PLoS One; 2015; 10(6):e0131108. PubMed ID: 26098881
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer induced by loss of Apc is restrained by TGFβ signaling.
Bjerke GA; Pietrzak K; Melhuish TA; Frierson HF; Paschal BM; Wotton D
PLoS One; 2014; 9(3):e92800. PubMed ID: 24651496
[TBL] [Abstract][Full Text] [Related]
20. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
